据Charles Daly和Sanne Wass报道，诺和诺德公司与瑞典Nanexa AB签署了一项价值高达11.65亿欧元（约13亿美元）的协议，获得其用于肥胖症和糖尿病治疗的药物递送技术权利。
By Charles Daly and Sanne Wass Novo Nordisk A/S signed a deal worth as much as €1.165 billion ($1.3 billion) with Sweden’s Nanexa AB for rights to its drug delivery technology for obesity and diabetes treatments.
根据Nanexa的声明，该协议授予诺和诺德全球独家许可，可使用Nanexa的原子层沉积药物递送技术平台用于某些治疗性肽类药物。诺和诺德将主导协议下产品的全球开发和商业化。交易包含6.15亿欧元的预付款。协议涵盖的适应症包括肥胖症和2型糖尿病。
The agreement gives Novo a global exclusive license to Nanexa’s Atomic Layer Deposition drug delivery technology platform for certain therapeutic peptide drugs, according to a statement from Nanexa. Novo will lead global development and commercialization of products under the deal.
Nanexa表示，协议还包括里程碑付款和“未来产品销售的低个位数版税”。
The deal includes €615 million in upfront payments, The agreement covers indications including obesity and type 2 diabetes. The accord also has milestone payments and “low single-digit royalties on future product sales,” Nanexa said.
Nanexa和诺和诺德已有合作历史，包括2022年关于该瑞典公司递送系统PharmaShell的协议。
Nanexa and Novo already have a history of cooperation, including a 2022 deal on the Swedish company’s delivery system PharmaShell. In addition, Nanexa’s chairman, Goran Ando, was on Novo’s board from 2005 to 2018 — with the last five years as chairman.
此外，Nanexa主席Goran Ando曾于2005年至2018年担任诺和诺德董事会成员，最后五年担任主席。
Nanexa and Novo already have a history of cooperation, including a 2022 deal on the Swedish company’s delivery system PharmaShell. In addition, Nanexa’s chairman, Goran Ando, was on Novo’s board from 2005 to 2018 — with the last five years as chairman.
Nordnet经济学家Per Hansen在致客户的报告中表示，诺和诺德获得了“一种它长期以来想要使用的技术”。
Novo is getting access to “a technology that it for long has wanted use,” Per Hansen, an economist at Nordnet, said in a note to clients. And while the deal is important for Novo, it’s “unlikely to be a short-term share price trigger.” “It’s certain that it will be a very good day for Nanexa’s shareholders,” Hansen added.
虽然该交易对诺和诺德很重要，但“不太可能成为短期股价触发因素”。
Novo is getting access to “a technology that it for long has wanted use,” Per Hansen, an economist at Nordnet, said in a note to clients. And while the deal is important for Novo, it’s “unlikely to be a short-term share price trigger.” “It’s certain that it will be a very good day for Nanexa’s shareholders,” Hansen added.
Hansen补充道：“这肯定会是Nanexa股东的一个非常好的日子。”
Novo is getting access to “a technology that it for long has wanted use,” Per Hansen, an economist at Nordnet, said in a note to clients. And while the deal is important for Novo, it’s “unlikely to be a short-term share price trigger.” “It’s certain that it will be a very good day for Nanexa’s shareholders,” Hansen added.